There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arcutis Biotherapeutics (ARQT – Research Report), Stereotaxis (STXS – Research Report) and NeoGenomics (NEO – Research Report) with bullish sentiments.
Arcutis Biotherapeutics (ARQT)
Mizuho Securities analyst Uy Ear maintained a Buy rating on Arcutis Biotherapeutics today and set a price target of $57.00. The company’s shares closed last Thursday at $10.22, close to its 52-week low of $7.25.
According to TipRanks.com, Ear is a 4-star analyst with an average return of
Currently, the analyst consensus on Arcutis Biotherapeutics is a Strong Buy with an average price target of $44.00.
See today’s best-performing stocks on TipRanks >>
NeoGenomics (NEO)
Craig-Hallum analyst Alexander Nowak maintained a Buy rating on NeoGenomics today. The company’s shares closed last Thursday at $16.24.
According to TipRanks.com, Nowak is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NeoGenomics with a $20.86 average price target, implying a 26.7% upside from current levels. In a report issued on June 5, SVB Securities also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARQT:
- Arcutis to Present at Upcoming Investor Conference
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Arcutis Announces Leadership Transition
- Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
- Arcutis Biotherapeutics completes enrollment in ITNEGUMENT-PED Phase 3 trial
